Morgan Stanley reissued their equal weight rating on shares of Hikma Pharmaceuticals Plc (OTC:HKMPF) in a report issued on Wednesday morning, Marketbeat reports.
HKMPF has been the subject of several other reports. ValuEngine upgraded shares of Hikma Pharmaceuticals Plc from a hold rating to a buy rating in a report on Thursday, July 27th. Numis Securities Ltd reiterated an add rating on shares of Hikma Pharmaceuticals Plc in a report on Friday, May 19th. Finally, Jefferies Group LLC cut shares of Hikma Pharmaceuticals Plc from a buy rating to an underperform rating in a report on Wednesday, May 17th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the stock. The company currently has an average rating of Hold and an average target price of $27.00.
Shares of Hikma Pharmaceuticals Plc (OTC:HKMPF) opened at 18.60 on Wednesday. Hikma Pharmaceuticals Plc has a 52-week low of $18.15 and a 52-week high of $29.75. The stock’s 50 day moving average is $20.32 and its 200-day moving average is $23.55. The firm has a market capitalization of $4.48 billion and a P/E ratio of 28.10.
ILLEGAL ACTIVITY WARNING: This article was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://stocknewstimes.com/2017/08/05/morgan-stanley-reaffirms-equal-weight-rating-for-hikma-pharmaceuticals-plc-otchkmpf.html.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.
